CalciMedica, Inc. (CALC)

Market Cap	26.83M
Revenue (ttm)	n/a
Net Income (ttm)	-13.70M
Shares Out	13.48M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,773
Open	2.070
Previous Close	2.070
Day's Range	1.989 - 2.150
52-Week Range	1.833 - 6.270
Beta	1.02
Analysts	Strong Buy
Price Target	17.25 (+766.83%)
Earnings Date	Mar 27, 2025

About CALC

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company’s lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an or...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: CALC
• Website: https://www.calcimedica.com

Analyst Forecast

According to 4 analysts, the average rating for CALC stock is "Strong Buy." The 12-month stock price forecast is $17.25, which is an increase of 766.83% from the latest price.

Price Target

$17.25

(766.83% upside)

Analyst Consensus: Strong Buy